Maxygen, Inc. (MAXY) - Financial and Strategic SWOT Analysis Review

Document Sample
Maxygen, Inc. (MAXY) - Financial and Strategic SWOT Analysis Review Powered By Docstoc
					         Maxygen, Inc. (MAXY) - Financial and Strategic SWOT Analysis Review
        Reference Code: GDPH31228FSA                                                                                          Publication Date: APR 2013

          411 Borel Avenue Suite 616                         Phone              +1 650 2412292                  Revenue          30 (million USD)
          San Mateo, CA                                      Fax                +1 650 2575892                  Net Profit       20.12 (million USD)
          94402                                              Website            www.maxygen.com                 Employees        6
                                                                                                                                 Pharmaceuticals           &
          United States                                      Exchange           MAXY [NASDAQ]                   Industry
                                                                                                                                 Healthcare

       Company Overview
       Maxygen, Inc. (Maxygen) is a biotechnology company. It focuses on the development of pegylated, granulocyte colony
       stimulating factor (G-CSF) for the treatment of chemotherapy-induced neutropenia (CIN) and acute radiation syndrome (ARS). G-
       CSF is a natural protein that functions by stimulating the body’s bone marrow to produce more white blood cells. The company's
       product pipeline consists of MAXY-G34, a product candidate being designed to be an improved next-generation G-CSF for the
       treatment of CIN. The product is also being evaluated for the treatment of ARS. The company operates along with its
       subsidiaries, namely, Maxygen ApS, in Denmark and the US.
       Key Executives                                                                SWOT Analysis
                       Name                                Title                      Maxygen, Inc., SWOT Analysis
         Isaac Stein                         Chairman                                 Strengths                              Weaknesses
         James R. Sulat                      Chief Executive Officer
                                                                                      Lead Product Candidate -               Challenges Related to MAXY-
         Louis    G.    Lange,      M.D., Director                                    MAXY-G34                               G34 (ARS)
         Ph.D.
                                                                                      Increasing Operational
         Gordon Ringold, Ph.D.               Director
                                                                                      Efficiency
         Ernest Mario, Ph.D.                 Director
        Source: Annual Report, Company Website, Primary and Secondary
        Research, GlobalData                                                          Opportunities                          Threats

       Share Data                                                                     Business Reorganization                Competitive Market
         Maxygen, Inc.
                                                                                      Emerging Markets                       Government Regulations
        Share Price (USD) as on 22-Apr-                                  2.44
        2013
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
        EPS (USD)                                                        0.73        GlobalData
        Market Cap (million USD)                                           68
        Enterprise Value (million USD)                                      5
        Shares Outstanding (million)                                       28
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData

       Financial Performance                                                         Recent Developments
                                                                                      Mar 12, 2013         Maxygen Reports 2012 Results
                                                                                      Nov 06, 2012         Maxygen Reports Q3 2012 Results
                                                                                      Aug 07, 2012         Maxygen Reports Q2 2012 Results
                                                                                      May 07, 2012         Maxygen Reports Q1 2012 Results
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData




       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData




Maxygen, Inc. (MAXY) - Financial and Strategic SWOT Analysis                                                                   Reference Code: GDPH31228FSA
Review
Source : www.globalcompanyintelligence.com                                                                                                                     Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 4
          List of Figures ................................................................................................................................................................................. 4
       Section 1 - About the Company.......................................................................................................................................................... 5
       Maxygen, Inc. - Key Facts .................................................................................................................................................................. 5
       Maxygen, Inc. - Key Employees ......................................................................................................................................................... 6
       Maxygen, Inc. - Key Employee Biographies ....................................................................................................................................... 7
       Maxygen, Inc. - Major Products and Services .................................................................................................................................... 8
       Maxygen, Inc. - Pharmaceutical Pipeline Products Data .................................................................................................................... 9
          Maxygen, Inc., Pipeline Products by Therapy Area ........................................................................................................................ 9
          Maxygen, Inc., Pipeline Products by Development Phase ............................................................................................................ 10
       Maxygen, Inc. - History ..................................................................................................................................................................... 12
       Maxygen, Inc. - Company Statement ............................................................................................................................................... 13
       Maxygen, Inc. - Locations And Subsidiaries ..................................................................................................................................... 15
          Head Office ................................................................................................................................................................................... 15
          Other Locations & Subsidiaries ..................................................................................................................................................... 15
       Section 2 – Company Analysis ......................................................................................................................................................... 16
       Maxygen, Inc. - Business Description .............................................................................................................................................. 16
       Maxygen, Inc. - Corporate Strategy.................................................................................................................................................. 17
       Maxygen, Inc. - SWOT Analysis ....................................................................................................................................................... 18
          SWOT Analysis - Overview........................................................................................................................................................... 18
          Maxygen, Inc. - Strengths ............................................................................................................................................................. 18
             Strength - Lead Product Candidate - MAXY-G34 ...................................................................................................................... 18
             Strength - Increasing Operational Efficiency ............................................................................................................................. 18
             Strength - Intellectual Property .................................................................................................................................................. 18
          Maxygen, Inc. - Weaknesses ........................................................................................................................................................ 18
             Weakness - Challenges Related to MAXY-G34 (ARS) ............................................................................................................. 18
          Maxygen, Inc. - Opportunities ....................................................................................................................................................... 19
             Opportunity - Business Reorganization ..................................................................................................................................... 19
             Opportunity - Emerging Markets ............................................................................................................................................... 19
             Opportunity - Rising Healthcare Expenditure in the US............................................................................................................. 19
          Maxygen, Inc. - Threats ................................................................................................................................................................ 19
             Threat - Competitive Market ...................................................................................................................................................... 19
             Threat - Government Regulations ............................................................................................................................................. 19
             Threat - Uncertain R&D Outcomes ........................................................................................................................................... 20
       Maxygen, Inc. - Key Competitors ..................................................................................................................................................... 21
       Section 3 – Company Financial Ratios ............................................................................................................................................. 22
       Financial Ratios - Capital Market Ratios........................................................................................................................................... 22
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 22
       Performance Chart ........................................................................................................................................................................... 24
       Financial Performance...................................................................................................................................................................... 24
       Financial Ratios - Interim Ratios....................................................................................................................................................... 25
       Financial Ratios - Ratio Charts ......................................................................................................................................................... 26
       Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 27
          Maxygen, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013...................................................................... 27


Maxygen, Inc. (MAXY) - Financial and Strategic SWOT Analysis                                                                                                   Reference Code: GDPH31228FSA
Review
Source : www.globalcompanyintelligence.com                                                                                                                                                                Pag
				
DOCUMENT INFO
Description: Maxygen, Inc. (MAXY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better. The profile contains critical company information including: - Business description – A detailed description of the company’s operations and business divisions. - Corporate strategy – Analyst’s summarization of the company’s business strategy. - SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats. - Company history – Progression of key events associated with the company. - Major products and services – A list of major products, services and brands of the company. - Key competitors – A list of key competitors to the company. - Key employees – A list of the key executives of the company. - Executive biographies – A brief summary of the executives’ employment history. - Key operational heads – A list of personnel heading key departments/functions. - Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company. - Key manufacturing facilities – A list of key manufacturing facilities of the company. - Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history. - Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history. Highlights Maxygen, Inc. (Maxygen) is a biotechnology company. It focuses on the development of pegylated, granul
BUY THIS DOCUMENT NOW PRICE: $125 100% MONEY BACK GUARANTEED
PARTNER GlobalData
GlobalData is an industry analysis specialist, providing business information products and services. GlobalData’s highly qualified team of analysts, researchers, and solution consultants use proprietary data sources, tools and techniques to gather, analyze and represent the latest and the most reliable information essential for a business to sustain a competitive edge. GlobalData is a UK-based company with presence across North America, Europe and Asia Pacific and has a broad product offering that ranges from interactive databases, reports and custom solutions. It is a comprehensive source of insights and analysis with coverage across the oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries. GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries. Sectors and Geographies Covered GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. Research Methodology With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries.